Brind.

Relay Therapeutics lowered its price target following the release of its Q2 financial results.

1 report, 1 independent Updated Aug 18

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Relay Therapeutics Raymond James

Keep exploring

The entities involved

Relay Therapeutics
company in Cambridge, United States
- Analyst reports compare market performance factors between Relay Therapeutics and I-Mab.Thu 13:53
Raymond James
Montreux Jazz Festival person ID 7418; keyboardist for Crosby, Stills & Nash
- Morgan Stanley assumed coverage of Airbnb stock, while Raymond James upgraded the rating and Matthew Condon raised the price target on September 27, 2026.Mon 02:32
- LPL Financial is acquiring Commonwealth advisors while facing competition from Osaic and recruitment efforts from Raymond James.Fri 21:53

Coverage

Newest first; wire copies grouped

Aug 18Insider MonkeyRaymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5. On August